PeriodontitisNCT07482878
Tinder Fungus as an Adjunct to Non-surgical Periodontal Therapy for Periodontitis
A study testing Tinder fungus-based formulation and Commercially available toothpaste in people with Periodontitis, run by Sigmund Freud PrivatUniversitat at 1 site in Austria.
Trial summary
The goal of this interventional clinical study is to learn if a Tinder fungus-based formulation -specifically a toothpaste and oral supplement powder-works as adjuncts to non-surgical periodontal therapy (NSPT) in patients with periodontitis. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Periodontitis
- What is being tested?
- Tinder fungus-based formulation and Commercially available toothpaste
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 70 participants
- Where
- 1 siteAustria
- Study dates
- Sep 2026to Dec 2028
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patients diagnosed with Stage III or IV periodontitis
- Patients who have not yet initiated periodontal therapy
- Patients who have at least 20 remaining teeth
- Patients who are willing to use an electric toothbrush
- Patients who are willing to use interdental brushes
Who cannot join
- Patients who have previously received treatment for periodontitis
- Patients who have already undergone or initiated periodontal therapy
- Patients with a known allergy or intolerance to any component of the toothpaste or the powder
- Patients who are already using a product that contains tinder fungus (Fomes fomentarius)
- Patients who, at the time of periodontal treatment, are undergoing active systemic cancer therapy (e.g., chemotherapy or immunotherapy) or radiotherapy in the head and neck region, or for whom such therapy is planned. Previous illnesses or completed therapies do not constitute an exclusion criterion, provided that no current or planned treatment exists that could influence the periodontal treatment outcome or pose an increased risk for the participants.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Austria1 site
Dental Clinic of the Sigmund Freud Private University
Vienna, State of Vienna, 1020
Hady Haririan, Prof,Dr,PhD,MSc, +4317201966, hady.haririan@med.sfu.ac.at
Brenda Laky, PD,MSc,PhD
About this study
Official title: Tinder Fungus (Fomes Fomentarius) as an Adjunct to Non-surgical Periodontal Therapy for Periodontitis: A Randomized Controlled Trial
The goal of this interventional clinical study is to learn if a Tinder fungus-based formulation -specifically a toothpaste and oral supplement powder-works as adjuncts to non-surgical periodontal therapy (NSPT) in patients with periodontitis.
The main questions it aims to answer is:
Read more
- Does the Tinder fungus-based formulation as an adjunct to NSPT reduce bleeding on probing more than a commercially available toothpaste as an adjunct to NSPT? Researchers will compare tinder fungus toothpaste and oral powder as an adjunct to NSPT to a commercially available toothpaste as an adjunct to NSPT to see if the Tinder fungus-based formulation works as adjuncts to NSPT in patients with periodontitis.
Participants will:
- Take tinder fungus toothpaste and oral powder or a commercially available toothpaste as an adjunct to NSPT twice daily for 30 consecutive days
- Visit the clinic at least twice including a visit before and after the intervention
- Keep a diary documenting their well-being and the number of times they used the toothpastes in the morning and evening.
- Conditions
- Periodontitis
- Being tested
- Tinder fungus-based formulation, Commercially available toothpaste
- Medical subject headings
- Periodontitis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Tinder fungus-based formulationOther
Participants will receive Tinder fungus (Fomes fomentarius)-based formulations including a toothpaste plus an oral supplement powder as adjuncts to non-surgical periodontal therapy (NSPT).
Commercially available toothpasteOther
A standard commercially available toothpaste administered as an adjunct to NSPT.
| Study group | Role | What they receive |
|---|---|---|
| Tinder fungus-based formulation (toothpaste and oral supplement powder) | Experimental | Tinder fungus toothpaste plus oral supplement powder as adjuncts to non-surgical periodontal therapy (NSPT) in patients with periodontitis Receives: Other: Tinder fungus-based formulation |
| commercially available toothpaste | Active comparator | Commercially available toothpaste as adjuncts to non-surgical periodontal therapy (NSPT) in patients with periodontitis Receives: Other: Commercially available toothpaste |
What is being measured
The primary outcome is the main question the study is designed to answer.
Bleeding on probing (BoP in %) change
Bleeding on probing (BoP in %) changes from baseline (T0) to reevaluation (T1). BOP will be recorded as yes/no for each of 6 sites and reported as the percentage of affected sites per participant.
Measured: changes from baseline (T0; 1 day before intervention starts) to reevaluation (T1; 5 weeks (±1 week) after intervention start)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted19 Mar 2026
- Study startSep 2026 (estimated)
- Primary completionDec 2027 (estimated)
- Study completionDec 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for PeriodontitisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 70 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Sigmund Freud PrivatUniversitat
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07482878
- Sponsor's protocol ID
- 19113705
- Status last verified
- Jan 2026
- First submitted
- 10 Mar 2026
- Last updated
- 16 Jul 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 16 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Tinder Fungus (Fomes Fomentarius) as an Adjunct to Non-surgical Periodontal Therapy for Periodontitis: A Randomized Controlled Trial
- ClinicalTrials.gov ID
- NCT07482878
- Acronym / sponsor ID
- 19113705
- Conditions
- Periodontitis
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 70 participants (estimated)
- Lead sponsor
- Sigmund Freud PrivatUniversitatUniversity, hospital or other
- Study start
- Sep 2026 (estimated)
- Primary completion
- Dec 2027 (estimated)
- Study completion
- Dec 2028 (estimated)
- First posted
- 19 Mar 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this interventional clinical study is to learn if a Tinder fungus-based formulation -specifically a toothpaste and oral supplement powder-works as adjuncts to non-surgical periodontal therapy (NSPT) in patients with periodontitis.
The main questions it aims to answer is:
- Does the Tinder fungus-based formulation as an adjunct to NSPT reduce bleeding on probing more than a commercially available toothpaste as an adjunct to NSPT? Researchers will compare tinder fungus toothpaste and oral powder as an adjunct to NSPT to a commercially available toothpaste as an adjunct to NSPT to see if the Tinder fungus-based formulation works as adjuncts to NSPT in patients with periodontitis.
Participants will:
- Take tinder fungus toothpaste and oral powder or a commercially available toothpaste as an adjunct to NSPT twice daily for 30 consecutive days
- Visit the clinic at least twice including a visit before and after the intervention
- Keep a diary documenting their well-being and the number of times they used the toothpastes in the morning and evening.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Tinder fungus-based formulation (toothpaste and oral supplement powder) | Experimental | Other: Tinder fungus-based formulationTinder fungus toothpaste plus oral supplement powder as adjuncts to non-surgical periodontal therapy (NSPT) in patients with periodontitis |
| commercially available toothpaste | Active comparator | Other: Commercially available toothpasteCommercially available toothpaste as adjuncts to non-surgical periodontal therapy (NSPT) in patients with periodontitis |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Patients diagnosed with Stage III or IV periodontitis
- Patients who have not yet initiated periodontal therapy
- Patients who have at least 20 remaining teeth
- Patients who are willing to use an electric toothbrush
- Patients who are willing to use interdental brushes
Key exclusion criteria (5 listed)
- Patients who have previously received treatment for periodontitis
- Patients who have already undergone or initiated periodontal therapy
- Patients with a known allergy or intolerance to any component of the toothpaste or the powder
- Patients who are already using a product that contains tinder fungus (Fomes fomentarius)
- Patients who, at the time of periodontal treatment, are undergoing active systemic cancer therapy (e.g., chemotherapy or immunotherapy) or radiotherapy in the head and neck region, or for whom such therapy is planned. Previous illnesses or completed therapies do not constitute an exclusion criterion, provided that no current or planned treatment exists that could influence the periodontal treatment outcome or pose an increased risk for the participants.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Tinder fungus-based formulationParticipants will receive Tinder fungus (Fomes fomentarius)-based formulations including a toothpaste plus an oral supplement powder as adjuncts to non-surgical periodontal therapy (NSPT). | Other | Tinder fungus-based formulation (toothpaste and oral supplement powder) |
| Commercially available toothpasteA standard commercially available toothpaste administered as an adjunct to NSPT. | Other | commercially available toothpaste |
Primary outcome
Bleeding on probing (BoP in %) change
Time frame: changes from baseline (T0; 1 day before intervention starts) to reevaluation (T1; 5 weeks (±1 week) after intervention start)
Bleeding on probing (BoP in %) changes from baseline (T0) to reevaluation (T1). BOP will be recorded as yes/no for each of 6 sites and reported as the percentage of affected sites per participant.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 16 Jul 2026.
- Individual participant dataSharing planned: Undecided
Related trials for Periodontitis
Recruiting
Effect of Cryotherapeutic and Nanotherapeutic Sodium Hypochlorite on Post-Operative Endodontic Pain.
Symptomatic Irreversible Pulpitis, Symptomatic Apical Periodontitis
Active, not recruitingObservational study
A Retrospective Comparative Evaluation of Omega-3 and Resveratrol Supplementation in Patients With Periodontitis
Periodontitis
Recruiting
Probiotics Versus Antibiotics as an Adjuvant to Non-surgical Periodontal Treatment Among Smokers With Stage II, Grade B Periodontitis
Probiotics, Antibiotics
Recruiting
Effects of Different Activation Techniques on Antimicrobial Photodynamic Therapy in Apical Periodontitis
Apical Periodontitis, Endodontic Retreatment
Recruiting
Ozone Gel Versus Chlorohexidine Gel as an Adjunct to Non-Surgical Treatment of Stage II Periodontitis Grade B Among Smokers Patients
Ozone Gel, Chlorohexidine Gel
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Dental Clinic of the Sigmund Freud Private University
Vienna, Austria
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Tinder fungus-based formulation and Commercially available toothpaste in people with Periodontitis, run by Sigmund Freud PrivatUniversitat at 1 site in Austria.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 16 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Austria. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Each site lists its own contact: choose the nearest one under Trial locations. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Bleeding on probing (BoP in %) change (time frame: changes from baseline (T0; 1 day before intervention starts) to reevaluation (T1; 5 weeks (±1 week) after intervention start)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Jul 2026.